Clinical trials: Thyroid Cancers
Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase II, non-randomized, open-label study to determine the efficacy of cabozantinib as a firstline treatment for patients with differentiated thyroid cancer (DTC). Subjects will receive drug at a starting dose of 60mg PO QD.
- Trial name
- NCT02041260
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Thomas Jefferson University
Differentiated Thyroid Cancer
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer.
- Trial name
- NCT05989425
- Testing
- surufatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Thyroid Cancer
Comparison of Quality of Life in Patients with Differentiated Thyroid Carcinoma Undergoing Different Surgery
The incidence of thyroid cancer has increased rapidly in recent years, especially in women. Early differentiated thyroid cancer has a good prognosis, and surgery is the main treatment.
- Trial name
- NCT06037174
- Testing
- minimally invasive procedure, Conventional Open Surgery
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thyroid Carcinoma, Hypothyroidism
The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma
The purpose of this study is to evaluate whether taking thyroid hormone medication with beverages other than water, decreases absorption of the medication by the intestine.
- Trial name
- NCT01707056
- Testing
- Black Coffee, Coffee with Milk, Black Tea
- Where
- 3 sites in United States
- Sponsor
- Medstar Health Research Institute
Thyroid Cancer
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment.
- Trial name
- NCT06980103
- Testing
- Decision Aid, Usual Care
- Where
- 3 sites in United States
- Volunteers
- 408 people
- Sponsor
- Georgetown University
Head and Neck Cancer, Parotid Gland Cancer
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when used with chemotherapy and radiation therapy in advanced head and neck cancer
- Conditions
- Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma
- Trial name
- NCT00405405
- Testing
- Cisplatin, Docetaxel, Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer
Optional Sub-study to Intraoperative Imaging With ICG Registry
The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.
- Conditions
- Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
- Trial name
- NCT02651246
- Testing
- data collection
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
The purpose of this study is to find out whether people who have had thyroid cancer develop resistance to treatment with thyroid hormones after having received high doses of thyroid drugs for many years.
- Trial name
- NCT04868045
- Testing
- Thyrotropin Releasing Hormone (TRH), levothyroxine, Hypothyroidism QOL questionnaire
- Sponsor
- Memorial Sloan Kettering Cancer Center
Medullary Thyroid Carcinoma
Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma
Medullary thyroid carcinoma (MTC) develops at the expense of calcitonin cells and is often characterized by lymph node metastases and sometimes visceral metastases.
- Trial name
- TEPCMT (NCT03636945)
- Testing
- PET at 18F-FDOPA
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Thyroid Cancer, Large Language Models
Evaluation of an Artificial Intelligence-enabled Clinical Assistant to Support Thyroid Cancer Management
This study aims to evaluate the clinical feasibility of adopting artificial intelligence (AI)-based models to improve clinical management of thyroid cancer.
- Trial name
- NCT07234539
- Testing
- AI-enabled clinical assistant
- Where
- 2 sites in Hong Kong
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Anaplastic Thyroid Cancer
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib…
- Trial name
- NCT03085056
- Testing
- Trametinib, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Prostate Cancer
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.
- Conditions
- Thyroid Cancer, Prostate Cancer, Neuroendocrine Tumors, SSTR Positive Tumors
- Trial name
- BCB RIV (NCT04104529)
- Testing
- Biological collection, tumor collection
- Where
- 4 sites in France
- Volunteers
- 350 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Cancer
Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing
We propose to study the prevalence of thyroid nodules and cancer in relation to radiation dose, in a defined cohort of Kazakhstan residents exposed as children to radioactive fallout from atomic bomb tests at the neighboring…
- Trial name
- NCT00341185
- Where
- Kazakhstan
- Volunteers
- 2,997 people
- Sponsor
- National Cancer Institute (NCI)
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma
- Trial name
- NCT03914300
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
The Incidence and Risk Factors of Radiotherapy Induced Hypothyroidism in Head and Neck Cancer With Long Term Follow up
This is a retrospective study with long term follow up to evaluate the incidence, timing and risk factors of radiotherapy induced hypothyroidism in non-thyroid head and neck cancer patients who were treated with RT alone or in…
- Trial name
- NCT03699098
- Testing
- TSH, T3, T4 and thyroid gland DVH
- Where
- Egypt
- Volunteers
- 101 people
- Sponsor
- Cairo University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.